|Table of Contents|

Clinical efficacy of 3DCRT combined with docetaxel/paclitaxel plus cisplatin(TP) concurrent chemoradiotherapy for Ⅲ stage non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 06
Page:
902-904
Research Field:
Publishing date:

Info

Title:
Clinical efficacy of 3DCRT combined with docetaxel/paclitaxel plus cisplatin(TP) concurrent chemoradiotherapy for Ⅲ stage non-small cell lung cancer
Author(s):
Zhou Houlong; Yang Yan; Li Qianwen; Zhang Chuang; Wei Shuzhen
Department of Oncology，No.82 Hospital，PLA，Jiangsu Huai'an 223001，China.
Keywords:
three dimensional conformal radiotherapy(3DCRT); concurrent chemoradiation; non-small cell lung cancer(NSCLC); curative effect
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2017.06.016
Abstract:
Objective:To analyzed the clinical efficacy of 3DCRT combined with docetaxel/paclitaxel plus cisplatin(TP) concurrent chemoradiotherapy for stage non-small cell lung cancer.Methods:In the study,a total of 86 cases with Ⅲ stage NSCLC in our in-patient department from January 2010 to October 2013 were analysed.These patients were divided into experimental group and control group,43 cases in each.The experimental group received 3DCRT combined with docetaxel/paclitaxel plus cisplatin(TP) concurrent chemoradiotherapy,while the control group was only acceppted by 3DCRT.Following with chemotherapy.After that,all the data,including responses,survival rate and toxicity were collected and analysed.Results:After analysis of these data,the respones rate of the experimental group was significantly higher than that of control group(81.40% vs 58.14%,P=0.019).The 2 year-survival tate of the experimental group was significantly higher than that of control group(51.16%vs 27.91%,P=0.027).Bone marrow toxicity reaction is significantly higher than the control group,but not present irreversible major complications after symptomatic treatment.Conclusion:The shot- and long-term clinical curative effect of chemoradiation for Ⅲ stage NSCLC patients is remarkable,toxic and adverse reaction does not affect the treatment plan.

References:

［1］Siegel R,Naishadham D,Jemal A.Cancer statistics,2012［J］.CA Cancer J Clin,2012,62:10-29.
［2］Morgensztern D,Ng SH,Gao F,et al.Trends in stage distribution for patients with non-small cell lung cancer:a national cancer database survey［J］.J Thorac Oncol,2010,5(1):29-33.
［3］Krzakowski M,Lucas C,Gridelli C.Fractionated scheme of oral vinorelbine as single-agent therapy or in combination with cispltin concomitantly with thoracic radiotherapy in stage Ⅲ non-small cell lung cancer:dose-escalation phaseⅠ ［J］.Clin Lung Cancer,2014,15(4):266-273.
［4］Zhang HL.The evolution and Response evaluation criteria in solid tumours［J］.Modern Oncology,2010,18(5):839-841.［张贺龙.实体瘤疗效评价标准及演变［J］.现代肿瘤医学,2010,18(5):839-841.］
［5］Zhi XY,Shi YK，Yu JM.Standards for the diagnosis and treatment of primary lung cancer (2015 version) in china［J］.Chin J Oncol,2015,37(1):67-78.［支修益，石远凯，于金明.中国原发性肺癌诊疗规范［J］.中华肿瘤杂志,2015,37(1):67-78.］
［6］Wao H,Mhaskar R,Kumar A,et al.Survival of patients with non-small lung cancer without treatment:a systematic review and meta-analysis ［J］.Systematic Reviews,2013,2:10-11.
［7］Curran WJ,Paulus R,Langer CJ,et al.Sequential vs concurrent chemoradiation for stage Ⅲ non-small cell lung cancer:Randonmized phase Ⅲ trail RTOG9410 ［J］.J Natl Cancer Inst,2011,103(19):1456-1460.
［8］Harris JP,Murphy JD,Hanlon AL,et al.A population-based comparative effectiveness study of radiation therapy techniques in stage Ⅲ non-small cell［J］.Int J Oncol Biol Phys,2014,88(4):872-884.
［9］Sher JD,Koshy M,Liptay MJ,et al.Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage Ⅲ non-small cell in the natinal cancer data bdse［J］.Cancer,2014,20(13):2060-2068.
［10］Jiang GC,Chen XY,Li Y,et al.Retrospective analysis of induction concurretn chemoradiotherapy with weekly docetaxel and cisplatin followed by surgery for stage Ⅲa-N2 non-small-cell lung cancer［J］.Chin J Thora Cardi Surg,2015,31(1):1-4.［姜冠潮，陈修远，李运，等.诱导同步放化疗联合手术治疗Ⅲa-N2期非小细胞肺癌－基于多西他赛与顺铂每周方案的疗效观察 ［J］.中华胸心血管外科杂志,2015,31(1):1-4.］
［11］Yang P,Pu XX,Shi YR,et al.Observation of concurrent chemoradiotherapy in the treatment of advanced non-small cell lung cancer［J］.J Clin pulmonarty Medicine,2013,18(8):1489-1490.［杨锫，蒲兴祥，师颖瑞，等.同步放化疗联合治疗晚期非小细胞肺癌的疗效观察 ［J］.临床肺科杂志,2013,18(8):1489-1490.］
［12］Shi SP,Han B.Research progress of different chemotherapy combined with radiotherapy for non-small cell lung cancer［J］.J Int Oncol,2015,42(5):381-384.［石砂硼，韩波.不同化疗方案同步放化疗方案治疗非小细胞肺癌的研究进展 ［J］.国际肿瘤学杂志,2015,42(5):381-384.］
［13］ Shen WB,Zhu SC,Su JW,et al.Analysis of long-term survival in patients treated with three-dimensional conformal radiotherapy for localy advanced non-small cell lung cancer［J］.Chin J Radiol Med Prot,2010,30:180-184.［沈文斌，祝淑钗，苏景伟，等.三维适形放射治疗局部晚期非小细胞肺癌长期生存分析［J］.中华放射医学与防护杂志,2010,30:180-184.］
［14］Auperin A,Le Pechoux C,Rolland E,et al.Meta-analysis of concomitant versus sequential radiontherapy in locally advanced non-small cell lung cancer ［J］.J Clin Cancer,2010,28(13):2181-2190.
［15］Kim WJ,Yang SH,Lee SH,et al.A phase Ⅲ randomized trial of cobined chemoradiotherapy versus radiotherapy alone in locally advanced non-small cell lung cancer［J］.Am J Clin Oncol,2002,25(3):238-243.
［16］Lan YH,Jiang XC,Xie FC,et al.Efficacy of IMRT combined with docetaxel concurretn chemoradiotherapy for patients with local advanced non-small cell lung cancer［J］.Anti-tumor Pharmacy,2014,4(5):379-382.［蓝玉宏，江晓聪，谢福川，等.调强放疗联合多西他赛单药同期化疗对老年局部晚期非小细胞肺癌的疗效分析［J］.肿瘤药学,2014,4(5):379-382.］

Memo

Memo:
国家高技术研究发展计划（863计划）基金资助（编号：2014AA020901）
Last Update: 2017-01-26